Financial Performance - The company's revenue for Q3 2022 was ¥499,312,414.08, a decrease of 63.87% compared to the same period last year[6]. - The net profit attributable to shareholders for Q3 2022 was ¥206,521,700.73, down 62.93% year-on-year[6]. - The net profit after deducting non-recurring gains and losses was ¥188,217,171.83, reflecting a decline of 65.83% compared to the previous year[6]. - The company reported a basic earnings per share of ¥0.5192, down 66.45% year-on-year[6]. - Net profit for the current period was ¥504,708,026.11, a decrease of 4.4% from ¥528,169,121.73 in the previous period[32]. - Basic and diluted earnings per share for the current period were 1.2904, compared to 1.4671 in the previous period[35]. Assets and Liabilities - The total assets at the end of Q3 2022 reached ¥7,173,842,560.89, an increase of 58.59% from the end of the previous year[6]. - The total assets increased to ¥7,173,842,560.89 from ¥4,523,446,917.50, showing strong growth in the company's asset base[28]. - The total liabilities decreased slightly to ¥1,696,840,935.11 from ¥1,715,354,421.76, indicating improved financial stability[28]. - The equity attributable to shareholders increased by 95.04% year-on-year, amounting to ¥5,477,001,625.78[6]. - The equity attributable to shareholders of the parent company rose to ¥5,477,001,625.78 from ¥2,808,092,495.74, reflecting strong retained earnings growth[28]. Cash Flow - The cash flow from operating activities showed a net outflow of ¥35,484,779.81, a significant decrease of 111.81% compared to the previous year[11]. - Cash inflow from operating activities totaled 967,781,400.50, down from 1,411,702,881.33 in the previous period, representing a decrease of approximately 31%[36]. - Net cash flow from operating activities was -35,484,779.81, a significant decline from 300,587,782.41 in the previous period[36]. - Cash inflow from investment activities was 4,331,189,120.42, compared to 2,265,110,874.30 in the previous period, indicating an increase of approximately 91%[39]. - Net cash flow from investment activities was -1,147,864,950.82, worsening from -644,256,999.76 in the previous period[39]. - Cash inflow from financing activities amounted to 2,554,768,800.00, up from 800,000,000.00 in the previous period[39]. - Net cash flow from financing activities was 1,964,579,300.01, compared to 591,522,222.12 in the previous period, showing a substantial increase[39]. - The ending balance of cash and cash equivalents was 896,022,620.53, up from 599,048,768.52 in the previous period[39]. - The company reported a net increase in cash and cash equivalents of 781,229,569.38, compared to 247,853,004.77 in the previous period[39]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,460[15]. - The largest shareholder, Hualan Biological Engineering Co., Ltd., holds 67.50% of shares, totaling 270,000,000 shares[15]. - The total number of preferred shareholders is not applicable, indicating no preferred shares were issued[18]. - The company has a total of 366,071,060 restricted shares at the end of the reporting period[21]. - The company plans to lift restrictions on 270,000,000 shares by August 18, 2025, which were issued before the initial public offering[18]. - The top ten shareholders do not have any known relationships or agreements that would classify them as acting in concert[17]. Expenses and Investments - The company experienced a 32.88% increase in sales expenses, totaling ¥636,720,642.53, due to increased marketing efforts[11]. - Total operating costs amounted to ¥1,007,106,441.39, up from ¥807,739,933.50, reflecting a significant increase in sales expenses[29]. - Research and development expenses were ¥110,099,858.88, slightly up from ¥108,705,277.49, indicating continued investment in innovation[29]. - The company has invested in new product development and market expansion strategies, although specific figures are not disclosed in the provided content[20]. Tax and Future Outlook - The company reported a significant increase in deferred income tax assets, rising to ¥197,459,746.95 from ¥182,899,117.57, suggesting potential future tax benefits[28]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[31]. Audit Status - The third quarter report was not audited[40].

Financial Performance - Hualan Biological reported a revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[21]. - The company achieved a net profit of RMB 300 million, which is a 10% increase compared to the same period last year[21]. - The company's operating revenue for the reporting period reached ¥1,060,557,926.68, a significant increase of 9,624.76% compared to the same period last year[29]. - Net profit attributable to shareholders was ¥298,186,325.38, marking a remarkable increase of 1,128.93% year-over-year[29]. - The net profit after deducting non-recurring gains and losses was ¥265,810,862.35, reflecting a 732.78% increase compared to the previous year[29]. - The company reported a total revenue of ¥249,502.74 million, an increase from ¥224,420.31 million, with a net profit of ¥94,552.37 million[66]. - The total profit for the first half of 2022 was ¥337,023,951.29, a significant turnaround from a loss of ¥47,665,924.26 in the first half of 2021[185]. - The company's basic earnings per share for the first half of 2022 was ¥0.7712, compared to a loss per share of -¥0.0805 in the same period of 2021[185]. Market Expansion and Product Development - User data indicates that the company has expanded its customer base by 20% in the first half of 2022, reaching a total of 1 million users[21]. - Hualan Biological plans to invest RMB 500 million in R&D for new vaccine technologies in the upcoming year[21]. - The company is targeting a revenue growth of 20% for the full year 2022, driven by new product launches and market expansion[21]. - Hualan Biological has successfully launched a new quadrivalent influenza vaccine, which is expected to capture 15% of the market share within the first year[21]. - The company is actively exploring potential acquisition opportunities to strengthen its market position and expand its product portfolio[21]. - The company is focused on expanding its market presence in the four-valent influenza vaccine sector, which has seen increased competition from other vaccine manufacturers[81]. - The company is actively developing multiple vaccines, including rabies and tetanus vaccines, to diversify its product offerings and mitigate risks associated with a narrow product range[79]. Financial Management and Investments - The company has established multiple core technology platforms for vaccine research and development, including an mRNA vaccine platform, and is actively conducting preliminary research on mRNA influenza vaccines[48]. - The company has invested ¥382,380 million in entrusted financial management, with a remaining balance of ¥261,661.68 million in unexpired financial products[71]. - The company reported investment income of ¥25,946,910.34, a substantial increase from ¥4,677,100.13 in the prior year, showcasing improved investment performance[185]. - The company received 2,254,768,800.00 in cash from financing activities, a substantial increase from 300,000,000.00 in the previous year[200]. - The net cash flow from financing activities was 2,167,012,633.35, compared to 95,511,388.82 in the first half of 2021[200]. Risk Management - Hualan Biological has identified key risks including regulatory changes and market competition, and has outlined strategies to mitigate these risks[21]. - The company identified risks related to a single product structure, with over 90% of revenue coming from influenza vaccines, which could impact profitability if market demand fluctuates[79]. - The company faces increasing competition in the vaccine market, which may lead to significant profit declines or losses[83]. - The company has established a comprehensive quality assurance system to mitigate risks related to product quality and ensure vaccine safety and efficacy[83]. Cash Flow and Financial Position - The net cash flow from operating activities for the first half of 2022 was -53,783,108.36, a significant decrease compared to 331,140,552.23 in the same period of 2021[194]. - The cash and cash equivalents increased by ¥893,034,043.65, a rise of 989.27% compared to ¥81,984,685.40 in the previous year[49]. - The company's total assets increased by 60.71% to ¥7,269,667,171.01 from the end of the previous year[29]. - The company's current assets amounted to RMB 5,013,289,419.91, up from RMB 2,529,227,166.81 at the start of the year, indicating a growth of approximately 98.5%[164]. - The company's accounts receivable rose to RMB 1,921,901,740.48, compared to RMB 1,438,966,174.92, reflecting an increase of approximately 33.5%[164]. Corporate Governance and Compliance - The company has not distributed cash dividends or bonus shares for the half-year period[90]. - The company has not engaged in derivative investments or entrusted loans during the reporting period, maintaining a conservative financial strategy[73][74]. - The company did not experience any bankruptcy reorganization matters during the reporting period[106]. - The company is committed to maintaining transparency and compliance with regulatory requirements as indicated by its disclosures[138].

Financial Performance - The company's revenue for Q1 2022 was ¥14,578,885.25, representing a 32.67% increase compared to ¥10,989,066.50 in the same period last year[5] - The net profit attributable to shareholders was -¥849,919.03, an improvement of 79.39% from -¥4,124,253.29 year-over-year[5] - The company reported a basic earnings per share of -¥0.0023, improving by 80.00% from -¥0.0115 in the same period last year[5] - The weighted average return on equity was -0.02%, an improvement from -0.19% year-over-year[5] - The total profit (loss) for the period was -7,297,154.69, an improvement from -10,534,334.31 in the previous period, indicating a reduction in losses[35] - The net profit (loss) attributable to the parent company was -849,919.03, compared to -4,124,253.29 in the previous period, showing a significant decrease in losses[35] Cash Flow - The net cash flow from operating activities was -¥51,709,044.15, a decline of 121.25% compared to ¥243,311,535.68 in the previous year[5] - Cash inflows from operating activities totaled 271,671,609.62, down from 595,713,661.48 in the previous period, reflecting a decline in cash generation[38] - Cash outflows from operating activities amounted to 323,380,653.77, compared to 352,402,125.80 in the previous period, indicating a decrease in cash outflows[38] - The net cash flow from investing activities was -469,050,302.04, worsening from -279,933,599.29 in the previous period[41] - Cash inflows from financing activities reached 2,254,768,800.00, compared to 300,000,000.00 in the previous period, indicating a substantial increase in financing[41] - The net increase in cash and cash equivalents was 1,730,171,953.82, significantly higher than 260,860,019.70 in the previous period[41] Assets and Liabilities - Total assets increased by 49.14% to ¥6,746,296,460.98 from ¥4,523,446,917.50 at the end of the previous year[5] - Total liabilities decreased slightly to CNY 1,694,850,780.34 from CNY 1,715,354,421.76, a reduction of 1.1%[28] - The equity attributable to the parent company increased significantly to CNY 5,051,445,680.64 from CNY 2,808,092,495.74, representing an increase of 79.3%[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 34,703, with the top ten shareholders holding 67.50% of the shares[12] - The top shareholder, Hualan Biological Engineering Co., Ltd., holds 270 million shares, representing 67.50% of the total shares[12] - The company has a total of 36 million shares held by Cyber Creator Limited, accounting for 9.00% of the shares[12] - The company has a total of 270 million shares under lock-up conditions, which are set to be released on August 18, 2025[16] Operational Highlights - The company raised ¥2,250,931,300.01 from financing activities, a significant increase of 656.66% compared to ¥297,482,083.31 in the previous year[7] - The company experienced a 75.18% decrease in operating costs, amounting to ¥234,777.35, attributed to vaccine returns and increased costs from a wholly-owned subsidiary[7] - The company reported a 77.56% increase in investment income, reaching ¥4,325,579.33, due to higher financial management returns[11] - Research and development expenses increased to CNY 35,308,146.72, up from CNY 31,389,740.69, indicating a growth of 12.3%[32] - The company plans to continue expanding its market presence and investing in new product development[30] - Future guidance indicates a focus on enhancing operational efficiency and exploring potential mergers and acquisitions[30] Inventory and Receivables - Inventory increased by 209.19% to ¥332,096,723.22, primarily due to an increase in raw materials and work-in-progress[7] - The company reported accounts receivable of approximately 1.206 billion RMB, down from 1.439 billion RMB at the beginning of the year[21] - The company has 1.029 billion RMB in trading financial assets, an increase from 825.82 million RMB at the beginning of the year[21] - The company's inventory increased to approximately 332.10 million RMB from 107.41 million RMB at the beginning of the year[21] Market Activity - The company has successfully registered a quadrivalent influenza virus split vaccine for children in February 2022[20]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2021, representing a year-on-year increase of 15%[18] - The net profit attributable to shareholders was RMB 300 million, which is a 10% increase compared to the previous year[18] - The company's operating revenue for 2021 was ¥1,829,813,885.72, a decrease of 24.59% compared to 2020[25] - The net profit attributable to shareholders for 2021 was ¥620,972,414.89, down 32.86% from the previous year[25] - The net profit after deducting non-recurring gains and losses was ¥585,412,142.79, reflecting a decline of 34.88% year-over-year[25] - The company achieved a total operating revenue of approximately ¥1.83 billion in 2021, a decrease of 24.59% compared to ¥2.43 billion in 2020[57] - Vaccine products accounted for 99.71% of total revenue, with a revenue of approximately ¥1.82 billion, down 24.63% year-on-year[57] - The gross profit margin for vaccine products was 88.20%, a decrease of 1.41% compared to the previous year[60] - The company reported a cash dividend of 2.00 yuan per 10 shares, totaling 80,002,000 yuan, which represents 100% of the distributable profit of 1,412,479,097.25 yuan[159] Market Expansion and Product Development - User data indicates that the company has expanded its customer base by 20% over the past year, reaching a total of 1 million users[18] - The company is focusing on the development of a new quadrivalent influenza vaccine, expected to launch in Q3 2022[18] - Market expansion efforts have led to a 25% increase in sales in international markets, particularly in Southeast Asia[18] - The management has set a revenue growth target of 20% for 2022, driven by new product launches and market penetration strategies[18] - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product portfolio[18] - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[129] - New product development includes a vaccine that is expected to enter the market by Q3 2022, with an estimated production capacity of 100 million doses annually[129] Research and Development - The company has allocated RMB 150 million for research and development in 2022, aiming to enhance vaccine efficacy and safety[18] - The company has established multiple core technology platforms to enhance its vaccine research and development capabilities[50] - The R&D expenditure for the year was 200 million RMB, accounting for 13% of total revenue, reflecting a commitment to innovation[129] - The company is accelerating the R&D progress of its projects, with several vaccines, including rabies and tetanus vaccines, already submitted for production approval[96] Operational Efficiency and Challenges - The company reported a net cash flow from operating activities of ¥569,328,674.62, a decrease of 17.93% compared to the previous year[25] - The sales volume of vaccine products decreased by 28.51% to approximately 15.54 million doses in 2021, compared to 21.73 million doses in 2020[61] - The inventory of vaccine products increased by 181.73% to approximately 9.50 million doses, primarily due to a decline in influenza vaccine sales during the overlapping vaccination seasons[61] - The company reported a decrease in operating costs by 14.37% year-on-year, attributed to the decline in sales volume[60] Governance and Compliance - The company has implemented a transparent governance structure, ensuring compliance with legal and regulatory requirements, and maintaining operational independence[106] - The board of directors operates efficiently with established committees, enhancing decision-making processes and governance standards[107] - The company has not experienced any changes in its board of directors, supervisors, or senior management during the reporting period[120] - The company has a complete procurement, production, and sales system, functioning as an organic whole[112] - The company has not engaged in any related party transactions that would compromise its independence[112] Social Responsibility and Market Position - The company is recognized as the largest influenza vaccine production base in China, with six listed products covering various vaccine categories[178] - The company emphasizes a commitment to social responsibility, aiming to harmonize economic and social benefits[179] - The company has actively participated in several national key scientific research projects related to vaccine development[179] Future Commitments and Shareholder Relations - The company plans to repurchase shares if the closing price falls below the audited net asset value per share from the previous fiscal year, with a repurchase amount not exceeding RMB 10 million per transaction[195] - The company commits to adhere to the measures for compensating diluted immediate returns[198] - The company will ensure compliance with legal obligations and disclosure requirements regarding related transactions[192]